TY  - CHAP
M1  - Book, Section
TI  - Granulomatosis with Polyangiitis
A1  - Manno, Rebecca L.
A1  - Yazdany, Jinoos
A1  - Tarrant, Teresa K.
A1  - Kwan, Mildred
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2023
N1  - 
T2  - Current Medical Diagnosis & Treatment 2023
AB  - Key  Clinical  Updates  in  Granulomatosis  with  PolyangiitisAmerican  College  of  Rheumatology/Vasculitis  Foundation  recommendations  favor  rituximab  as  first-line  induction  therapy.  Cyclophosphamide  may  also  be  used  for  induction  therapy.  Avacopan  is  FDA-approved  as  add-on  treatment  for  severe  ANCA-associated  vasculitis  induction  therapy  in  combination  with  rituximab  or  cyclophosphamide  plus  corticosteroids.For  nonsevere  disease  without  life-  or  organ-threatening  manifestations,  methotrexate  up  to  25  mg  oral  or  subcutaneous  weekly,  plus  corticosteroids  may  be  effective  induction  therapy.Rituximab,  dosed  at  a  fixed  interval  of  1  g  every  6  months  or  500  mg  every  4  months,  is  favored  as  first-line  maintenance  treatment.Chung  SA  et  al.  Arthritis  Rheumatol.  [PMID:  34235894]Jayne  DRW  et  al;  ADVOCATE  Study  Group.  N  Engl  J  Med.  [PMID:  33596356]  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1193125814
ER  -